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Abstract: Chimeric Antigen Receptor (CAR) T-cell therapy has demonstrated high rates of response
in recurrent B-cell Acute Lymphoblastic Leukemia in children and young adults. Despite this success,
a fraction of patients’ experience relapse after treatment. Relapse is often preceded by recovery of
healthy B cells, which suggests loss or dysfunction of CAR T-cells in bone marrow. This site is harder
to access, and thus is not monitored as frequently as peripheral blood. Understanding the interplay
between B cells, leukemic cells, and CAR T-cells in bone marrow is paramount in ascertaining the
causes of lack of response. In this paper, we put forward a mathematical model representing the
interaction between constantly renewing B cells, CAR T-cells, and leukemic cells in the bone marrow.
Our model accounts for the maturation dynamics of B cells and incorporates effector and memory
CAR T-cells. The model provides a plausible description of the dynamics of the various cellular
compartments in bone marrow after CAR T infusion. After exploration of the parameter space, we
found that the dynamics of CAR T product and disease were independent of the dose injected, initial
B-cell load, and leukemia burden. We also show theoretically the importance of CAR T product
attributes in determining therapy outcome, and have studied a variety of possible response scenarios,
including second dosage schemes. We conclude by setting out ideas for the refinement of the model.
Keywords: CAR T; mathematical model; acute lymphoblastic leukemia; B cell; bone marrow
1. Introduction
Chimeric antigen receptor (CAR) T-cell therapy is an immunotherapy technique con-
sisting of the genetic modification of T-cells to allow them to recognize specific tumor
antigens. The CAR T product is built by obtaining T-cells from the patient’s blood, and en-
gineering and expanding them in the laboratory. The product is then re-infused into
the patient for therapeutic purposes [1]. This is regarded as one of the most promising
therapeutic advances in the fight against cancer, and is now integrated into standard care
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for some hematological malignancies [2,3]. The most successful instance of CAR T ther-
apy is its application to B-cell malignancies, especially when aimed at T-cells bearing the
B-cell common antigen CD19. This marker is widely expressed in B cells but is absent
from other cell types [4], making it an ideal target for immunotherapy. High response
rates have been reported in B-cell Acute Lymphoblastic Leukemias and in Diffuse Large
B-cell Lymphomas [5–7], leading to the approval of several CAR T products by different
regulatory agencies [8,9].
This paper focuses on the use of CAR T in B-cell childhood Acute Lymphoblastic
Leukemia (ALL). This cancer comprises 80% of pediatric leukemias, which account for
25% of all pediatric malignancies [10]. The rate of cure of B-cell ALL has been increasing
steadily thanks to improvements in chemotherapy regimes, with around 80% of children
achieving complete remission [11]. Prognosis is much worse for patients who experience
relapse. This set of patients usually receives additional chemotherapy cycles and possibly
hematopoietic progenitor transplants, which are frequently ineffective [12]. It is in this
group of highly treated patients that a good rate of response to CAR T therapy has been
observed [13]. Clinical trials have shown that CAR T-cells are able to expand in vivo,
eliminate leukemia burden, and persist in the patient for as long as two years [6,14–16].
Despite this success, 30 to 50% of patients still experience long term relapse [17].
Moreover, 20% of patients fail to achieve remission after CAR T infusion. Some fraction
of these relapses are caused by what has been termed “antigenic escape,” meaning that
leukemic cells lose expression of the CD19 antigen and thus avoid the targeted action
of CAR T-cells. CD19+ relapse, on the other hand, is related to a lack of expansion or
persistence of the product [3]. Clinical trials and associated research have found conflicting
evidence regarding the relationship between dose, leukemia burden, and response. It has
been pointed out that the reasons for treatment failure may be drug-intrinsic, probably
related to characteristics of the patient’s T-cells before extraction and manufacturing [18,19].
CAR T therapy presents a number of treatment-associated toxicities, the most impor-
tant of which is the so-called cytokine release syndrome (CRS). This condition is related to
the fast action of T-cells against CD19+ cells, and therefore linked to the level of CAR ex-
pansion and leukemia burden. Neurotoxicity is another, less elucidated side effect. Finally,
B-cell aplasia (BCA) is a kind of on-target off-tumor toxicity due to the fact that healthy
B cells also express CD19 [20,21]. In fact, BCA in peripheral blood is used as a surrogate
marker for CAR T persistence, and loss of BCA is associated with a higher probability of
disease recurrence [22,23]. This is because new B cells are continuously being generated in
the bone marrow, providing an endless source of stimulation for the CAR T-cell population
and acting as an endogenous vaccine [24]. In this regard, it is important to note that most
data about the outcome of the therapy, such as absolute leukocyte count, cytokine levels,
or B cell and CAR T number, come from peripheral blood samples. However, leukemia
is a disease of the bone marrow, where blood cells are produced. From that perspective,
peripheral blood can be thought of only as a surrogate marker, since what is observed in
blood has probably occurred before or is linked to what has previously occurred in bone
marrow. Obtaining aspirates or bone marrow biopsies are more invasive procedures and
are not carried out as often as peripheral blood extraction. Thus, data on relevanT-cellular
components in bone marrow dynamics are scarce. Recent studies related to clinical trials
have nonetheless recognized the importance of tracking bone-marrow dynamics [24].
This is where mathematical modeling comes into play. Mathematical models have a
long history of application been applied in biology, medicine, and oncology. Like animal
models, mathematical models offer a simplified representation of a system, providing a
tool to explore causal relations and mechanisms. As a recent therapeutic breakthrough,
CAR T therapy is starting to lend itself to a mathematical characterization [25]. While there
are some studies involving solid tumors [26,27], most focus on hematological malignancies,
given the success obtained in this group of cancers. There are general models of leukemia
and lymphoma [28–31] and more specific applications in B-cell lymphoma [32], B-cell
chronic lymphoblastic leukemia [33], T-cell ALL [34], and B-cell ALL [35,36].
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By integrating mathematical models of B-cell development and T-cell response, the aim
is to describe the interaction between cancerous cells, healthy B cells and CAR T-cells,
with the purpose of reproducing and shedding light on the clinical features typically
observed in clinical trials. This can also provide a platform for testing hypotheses related
to the success or failure of the therapy and for discussing matters related to the response of
T-cells to antigen stimulation.
2. Mathematical Model
2.1. Main Elements of the Model
A schematic representation of the compartments and mechanisms accounted for in
our mathematical model is shown in Figure 1. There are three main elements. The first is
the production of B cells, a sequential process in which cells transit from Pro-B cells (B-cell
progenitors that do not yet express the characteristic CD19 surface marker) to immature
B cells which exit the bone marrow to complete maturation elsewhere. There are two
intermediate steps which are usually called Pre-BI and Pre-BII [37]. This follows the typical
compartmentalization of B-cell development [38]. The second element of the model is the
leukemic cells. They arise from one of the precursor stages of B-cell development, either
Pre-BI or Pre-BII, and exit the normal maturation route. They then proliferate with the only
restriction of available bone marrow space. Some of these leukemic cells can exit the bone
marrow and manifest in peripheral blood. Finally, CAR T-cells are infused in peripheral
blood and then travel to the bone marrow in order to engage with CD19+ cells. They
proliferate on encountering them and differentiate into effector cells, inducing the death
of antigen-bearing cells and dying shortly afterwards. Part of the expanded population
differentiates into long-lived memory cells that retain the ability to proliferate again upon
repeated exposure to the antigen [39].
2.2. Hematopoietic and Leukemic Compartments
We described healthy bone marrow by means of compartments Bi = Bi(t), where
i = 0, 1, 2, 3 represents different stages of maturation of B lymphocytes. B0 are the B-cell
progenitors or Pro-B cells, which do not yet express the B-cell antigen CD19; B1 are early or
Pre-BI cells; B2 are intermediate or Pre-BII cells; and B3 are late or immature B cells, ready
to enter the blood and complete maturation elsewhere. These three last stages already
express the marker CD19. The leukemic clone is given by L(t). The mathematical model
for the disease without treatment reads:
dB0
dt
= sBρ0B0 − γ0B0, (1)
dB1
dt
= sBρ1B1 + γ0B0 − γ1B1, (2)
dB2
dt
= sBρ2B2 + γ1B1 − γ2B2, (3)
dB3
dt
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Figure 1. B cells progressively express CD19 as they become more mature. Four maturation stages were considered, namely
Pro B, Pre BI, Pre BII, and immature B cells. These cell types were assumed to proliferate with rate ρi (i = 0, . . . , 2) and
progress with rates γj (j = 0, . . . , 3), except for immature B cells that no longer proliferate, leaving bone marrow with an
exit rate γ3. Leukemic cells originate from a B-cell precursor and proliferate with rate ρL, invading the bone marrow and
eventually migrating to peripheral blood with an exit rate γL. CAR T-cells are assumed to travel to bone marrow from
blood and proliferate with rate ρC upon encounters with CD19-expressing cells. They carry out effector functions on CD19
expressing cells with killing capacity α. Pro-B cells are not affected by this action since they do not express CD19. Part of
the activated CAR T pool becomes long-lived memory cells with rate γAM. These cells can regain effector function upon
repeated exposure to CD19, with reactivation rate γMA.
This paper looks at two main biological processes within each B-cell compartment:
proliferation ρi and maturation γj. In previous works, we followed the hypothesis that the
regulation of cell production occurs through a negative feedback signal affecting prolif-
eration sB(t), where k represents the intensity of the signal [40]. This compartmentalized
structure with proliferation, maturation, and regulatory feedback has already been used in
mathematical models of B-cell hematopoiesis [41]. In this case, the leukemic clone inter-
venes in this process by inhibiting the growth of healthy B cells. Leukemic cells, however,
can avoid self-inhibition and proliferate (ρL) with the restriction of bone marrow space
Lmax, invading the bone marrow and leading to a shortage of healthy immune cells [42]
(Note that saturation is rarely achieved due to therapeutic action). A different signaling
function sL(t) was therefore specified, without the clone. We assumed that leukemic cells
and B-cells both employ the same processes (e.g., cytokine secretion) for this inhibition,
and that the larger influence of leukemia is due to their exaggerated growth rather than
to different intensity of inhibition. We thus specified the same intensity k for both cell
types. Finally, we assumed that the invasive character of the clone allows it to exit the
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bone marrow with rate γL and thus be found in blood, which allows it to eventually settle
somewhere else [10].
2.3. CAR T-Cell Compartment
Several studies have incorporated CAR T-cells in the form of a compartment that
expands and acts on B cells and cancer cells [26,32,34–36]. However, clinical evidence
suggests that a better description of the dynamics can be achieved by considering two
subpopulations [22–24]. This aligns with previous models of immune T-cell response,
which considered three compartments for the T-cell populations: naïve, activated or
effector, and memory cells [43]. Some models of CAR T response have also included
this feature [28,31,33]. The process of T-cell response can be summarized as follows:
Naïve T-cells enter the system and activate after encountering the corresponding antigen.
Activated T-cells then undergo fast expansion and carry out effector functions on the
antigen-bearing cells. The majority of this expanded pool die shortly after, but part of these
cells become memory T-cells that can reactivate if they encounter the antigen again in the
future. The intricacies of this dual differentiation into effector and memory are not yet fully
understood [44,45]. The mathematical representation of de Boer et. al. [46], who fitted data
of T-cell response to lymphocytic choriomeningitis virus, has been followed here. This
infection induces a persistent immune response and therefore can be helpful in simulating
CAR T response. In our case, we assumed naïve cells to come from a single infusion and
become activated over a short period of time, thereby omitting the corresponding equation.
We denote activated cells by CA(t), and memory cells by CM(t). Adding these equations
to model (1)–(7) yields:
dB0
dt
= sHρ0B0 − γ0B0, (8)
dB1
dt
= sHρ1B1 + γ0B0 − γ1B1 − αB1CA, (9)
dB2
dt
= sHρ2B2 + γ1B1 − γ2B2 − αB2CA, (10)
dB3
dt








− γLL − αLCA, (12)
dCA
dt
= F(t)(ρCCA + γMACM)−
1
τA
CA − (1 − F(t))γAMCA, (13)
dCM
dt
= (1 − F(t))γAMCA −
1
τM








∑3i=1 Bi + L
) . (15)
Activated cells CA(t) proliferate with rate ρC and become memory cells CM(t) with
rate γAM. These processes are modulated by the activation function F(t). This is a contin-
uous function of the level of antigen, and takes values on the interval [0, 1]. It has been
shown previously that a Michaelis–Menten function provides an appropriate functional
form [47], saturating for extended antigen exposure. The Michaelis–Menten constant h
represents the number of CD19 expressing cells for which activation is half-maximal; we
therefore renamed this parameter to activation threshold. This saturating function allowed
us to explicitly consider in the model the fact that there is a limit for proliferation during
activation, which is not the case in predator–prey models: T-cells commit to a clonal expan-
sion of a given size upon activation of the first parent T-cell [44,48]. Activated cells can also
come from memory cells with rate γMA, a process that again depends on the activation
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function. When the amount of antigen decreases, proliferation and activation decrease
and transition to memory is initiated, thus the term (1 − F(t)). With respect to lifetimes,
activated cells die with a characteristic time τA of the order of days. Memory cells come
from activated cells and have a longer lifetime τM. They become activated again when
the activation function F(t) grows. Finally, the equations for the CD19+ compartments,
namely B1(t), B2(t), B3(t), and L(t), include an additional mass action term representing
elimination by activated CAR T-cells CA(t), with killing capacity α [49].
To sum up, the major assumptions of the model are: (i) the B-cell developmental
dynamics specified as a proliferation and maturation process with inhibitory feedback;
(ii) the leukemic clone growing without self-inhibition; and (iii) the CAR T population
consisting of activated and memory cells controlled by a saturating activation function.
2.4. Parameter Estimation
We studied proliferation and differentiation parameters in a previous work [40], where
the evolution of the three CD19+ cellular compartments (B1, B2, and B3) was compared
to clinical and literature data to obtain characteristic parameter values. We followed the
reasoning in that work to provide values for the Pro-B compartment and for the leukemic
cell population. A more detailed explanation and references to experimental works can
be found in the Supplementary Information. For the CAR T-cell compartment, typical
parameter values can be obtained from studies of Tisagenlecleucel kinetics, the FDA-
approved CAR T product for B-cell ALL [23,24]. There, the authors fitted patient data to a
mixed-effects model and provided values for proliferation rate ρC, memory transition rate
γAM, and both activated and memory characteristic lifetimes τA and τM. The estimation of
the rest of parameters is detailed in the Supplementary Information. All parameter values
and their meanings are listed in Table 1.
To simulate Equations (8)–(14), we also had to set the initial conditions for the dif-
ferent compartments. For B cells, we started from the homeostatic concentrations that
can be obtained by simulating only Equations (1)–(4). Alternatively, these proportions
can be found in ref. [40]. The total B-cell population in these conditions would be around
3 × 1010cells. CAR T-cell patients, however, undergo a preparatory chemotherapy to re-
move the host’s lymphocytes (lymphodepleting chemotherapy), so the B-cell population
should be substantially smaller. We select as the initial state 1% of that amount leading
to a B-cell population of around 3 × 108 cells. With respect to the leukemic clone, clinical
trials of CAR T therapy in B-cell ALL report leukemia burden ranging from less than
1% to almost 100% of bone marrow mononucleated cells [15,16]. We therefore selected
an initial leukemia burden in the range 1010–1012. Finally, CAR T dose was carefully
selected in early clinical trials and lies approximately in the range 0.1 to 5 × 106 cells
per kg [6,14–16]. After infusion, CAR T-cells in blood decrease sharply due to their distribu-
tion to the tissues [22]. We can assume that a substantial part of the product is transferred
to the bone marrow, where the majority of the CD19 antigen is concentrated. Taking into
account pediatric weights, we selected the range of 107–108 cells injected.
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Table 1. Parameter values for the biomathematical model given by Equations (8)–(14).
Parameter Meaning Value Units
ρ0 Pro-B proliferation rate ln(2)/8 day−1
ρ1 Pre-BI proliferation rate ln(2)/1 day−1
ρ2 Pre-BII proliferation rate ln(2)/1.5 day−1
γ0 Transition rate: Pro-B to Pre-BI 0.02 day−1
γ1 Transition rate: Pre-BI to Pre-BII 0.168 day−1
γ2 Transition rate: Pre-BII to Immature 0.144 day−1
γ3 Blood exit rate 0.288 dayt−1
k Signal intensity 10−10 cell−1
ρL Leukemic cell proliferation rate ρ1 day−1
Lmax Leukemic cell carrying capacity 1012 cell
γL Leukemic cell blood exit rate 0.001 · γ3 day−1
α Activated CAR T killing capacity 3 × 10−9–3 × 10−11 day−1· cell−1
ρC Activated CAR T proliferation rate 0.9 day−1
τA Activated CAR T mean lifetime 6.5 day
γAM Activated to memory transition rate 0.001 day−1
γMA Memory to activated transition rate 0.33 day−1
τM Memory CAR T mean lifetime 300 day
h CAR T activation threshold 108–1011 cell
2.5. Computational Details
The system of Equations (8)–(14) was solved numerically with the scientific software
package Matlab (R2019a, The MathWorks, Inc., Natick, MA, USA), run in a 4-core 16 GB
RAM 3.4 GHz iMac. The command employed was ode45, which uses an explicit Runge–
Kutta formula of 4–5 order (Dormand–Prince) and adaptive step size. Plots were produced
in the same software and exported using an export_fig package.
3. Results
3.1. The Mathematical Model without B-Cell Development Reproduces Clinical Data
Most clinical data obtained in CAR T clinical trials are based on peripheral blood
samples. Typical curves for CAR T dynamics can be found in refs. [22–24]. The usual time
course of a successful therapy is as follows: After infusion, CAR T-cells are distributed
around the body. Next, encounters with leukemic cells or B cells trigger activation and
expansion of the CAR T population. After approximately ten days of proliferation, CAR
T-cells have already expanded by two orders of magnitude or more. Following elimination
of the targeT-cells, CAR T-cell numbers undergo a biphasic decline, consisting of an initial
fast decay or contraction phase and a slow decay or persistence phase. Peripheral blood,
however, lacks the constant production of B cells of the bone marrow, and so we expect
the dynamics to be different. Therefore, in order to compare our model with data in blood,
the production of B cells during the first post-therapy stages was neglected, as done in [36],
and only Equations (12)–(14) were simulated. The initial state was lowered by one order
of magnitude to simulate peripheral blood conditions. An example of such simulation is
shown in Figure 2.















Figure 2. Dynamics of leukemic cells and CAR T-cells without new B-cell generation. Simulation of the evolution over time
of leukemic cells (solid gray line), total CAR T-cells (solid orange line), and memory CAR T-cells (dotted orange line). In this
simulation, we used only Equations (12)–(14), so we observed no recovery of B cells. The initial state was L(0) = 2 × 1010
cells, CA(0) = 5 × 106 cells, and CM(0) = 0 cells. Parameters were as in Table 1 with α = 3 × 10−10 day−1 · cell−1 and
h = 5 × 108 cells. (A) dynamics for the first month of therapy; (B) dynamics for the first nine months of therapy.
Note that, while the system is describing the bone marrow and some parameters
would not appear in peripheral blood (like carrying capacity), we can still recapitulate the
basics of the interaction between CAR T-cells and leukemic cells. We observed an initial
phase lasting around 10 days of CAR T expansion, during which the leukemic cells still
had some time to expand. After the CAR T-cells had completed a two-fold expansion,
and were mainly composed of effector cells, leukemic cells decreased and eventually
disappeared (Figure 2A). The CAR T-cell population then contracted rapidly as activated
cells died. Memory CAR T-cells remained, accounting for the slow decay phase (Figure 2B).
The magnitude of the expansion and contraction and the characteristic times involved in
the response agreed with typical clinical data. This simulation allowed us to confirm the
validity of the ranges chosen for the parameter values, especially the killing capacity α and
the activation threshold h. In this way, we ensured that the results that included B-cell
production were reliable.
3.2. Effector and Memory CAR T-Cells Are Able to Control the Disease
We next analyzed bone marrow expansion scenarios and simulated the model with the
complete set of equations. Examples of the results are shown in Figure 3A. During the first
30 days, we observed behavior similar to that of Figure 2B: Early CAR expansion followed
by depletion of all CD19+ cells, healthy and malignant. Pro-B cells increased steadily
in the meantime, in response to the shortage of mature B cells. From day 30 onwards,
healthy B cells started to recover. Around day 50, CAR T-cells responded to this increase:
memory cells reactivated and CAR T expanded again. Cycles of CAR T expansion and
B-cell reduction ensued, and, after six months, all cell types had reached a steady state
and the disease had been controlled. This simulation explains the role of B cells as an
endogenous vaccine. Instead of the expected number of activated cells in peripheral
blood, we observed their reactivation due to CD19 antigen recovery. The steady although
significantly lower level of self-renewing B cells kept CAR T-cells in a state of engagement,
explaining their persistence.
An interesting prediction coming from this simulation is the change in the distribution
of the B-cell population as a result of the therapy. In Figure 3B, we see the proportion
of cells in each subset in homeostatic conditions and the new distribution after therapy.
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In the latter, B cells were mainly composed of the CD19− Pro-B cell compartment, and the
remaining compartments were ordered according to their maturation stage. In normal
conditions, the Pre-BII compartment is the most abundant, followed by the immature
compartment [38,40]. Reports of successful CAR T therapy in B-cell malignancies indicate
BCA in peripheral blood as a marker of therapy response [14–16]. While this seems to be in
contradiction with the results presented here, where we observe a recovery of B cells, this is
actually due to the sensitivity of clinical detection. Indeed, here the immature compartment
in the steady state after therapy is composed of approximately 106 cells, barely 0.0002% of
the total bone marrow capacity. This means that the small number of B cells in blood would
go undetected. Thus, BCA in peripheral blood would be compatible with the attempts at B












Figure 3. Successful control of the disease in bone marrow. (A) dynamics of Equations (8)–(14). Simulation now includes B
cells: Pro-B cells (solid blue line), Pre-BI cells (dashed blue line), Pre-BII cells (dashed-dotted blue line), and Immature B
cells (dotted blue line). Initial state is B0(0) = 106 cells, B1(0) = 3 × 107 cells, B2(0) = 2 × 108 cells, B3(0) = 9 × 107 cells,
L(0) = 2× 1011 cells, CA(0) = 5× 107 cells and CM(0) = 0 cells. Parameters are those of Table 1 with α = 3× 10−10 day−1 ·
cell−1 and h = 109 cells; (B) proportions of B cell subsets in bone marrow, relative to the total B-cell population, under normal
conditions (light blue) and after successful CAR T therapy (dark blue). Density plots are a continuous representation of the
proportions, obtained with shape-preserving piecewise cubic interpolation using Matlab’s function interp1.
3.3. Initial State Does Not Affect CAR T Expansion and Outcome
We next studied the effect of the initial state on therapy outcome and CAR T expansion.
Clinical trials have investigated the safe dosage regime and the influence of leukemic cells
and initial B-cell population. In Figure 4, we show the results obtained for different
initial values for leukemic cells (A), total B cells (B), and CAR T-cells (C). None of these
factors had an impact on the expansion and final outcome of the therapy, for a range
of parameters justified with clinical information (see parameter estimation). The major
effect was a small delay of up to three days in expansion when varying the CAR T dose
by an order of magnitude. This agrees with clinical reports returning no dose–exposure
relationship [14–16] and no clear influence of leukemia burden on CAR T expansion [22–24].
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The explanation could lie in the fact that T-cells expand in vivo in response to stimulation,
but in an antigen-independent manner [50,51], meaning that, once activated, they commit
to an expansion of a given size, i.e., a constant proliferation rate This would also explain
why therapy failure seems to be more closely linked to the characteristics of the product
rather than to the characteristics of the disease. We will address this point in more detail in
the next subsection.
(A) (B) (C)
Leukemic cellsLeukemic cells Leukemic cells




B(0) = 3.2 × 1010
B(0) = 3.2 × 109
B(0) = 3.2 × 108
C(0) = 1 × 108
C(0) = 5 × 107
C(0) = 1 × 107
Figure 4. Influence of initial leukemia load, B-cell level, and CAR T dose on therapy outcome. Evolution with time
of leukemic cells (gray) and total CAR T-cells (orange) for different initial configurations (In decreasing order: solid,
dashed, dotted lines). When unchanged, initial values are B0(0) = 106 cells, B1(0) = 3 × 107 cells, B2(0) = 2 × 108 cells,
B3(0) = 9 × 107 cells, L(0) = 2 × 1011 cells, CA(0) = 5 × 107 cells and CM(0) = 0 cells. Parameters are those of Table 1 with
α = 3 × 10−10 day−1 · cell−1 and h = 109 cells. (A) influence of leukemia burden; (B) influence of initial B-cell population,
defined as the sum of all B-cell compartments; (C) influence of CAR T dose.
3.4. CAR T Product Characteristics Determine Therapy Success or Failure
We have previously shown an example of disease control (Figure 3). Having noted
the limited influence of the initial state on therapy outcome, we turned to CAR T product
characteristics to see whether we could explain scenarios of lack of response. As discussed
in the Introduction, there are two kinds of relapse, CD19− and CD19+. In order to simulate
the former, we would need to describe CD19 expression with a continuous variable or
include a CD19− leukemic clone compartment. We therefore restricted the analysis to
CD19+ relapses. Clinical trials agree that non-responding patients show limited and
slower CAR T expansion and shorter persistence, being unable to remove the cancer
completely [14–16].
In order to reproduce this scenario, we explored the space of parameters delimited by
α, the killing capacity of CAR T-cells; h, the activation threshold; and ρC, the proliferation
rate, the three parameters related to CAR T-cells and their action. We first simulated the
model for different values of one parameter while keeping the other two constant. Results
for the first 30 days of treatment are shown in Figure 5. Contrary to what happened with
the initial state, here we observed changes in fold expansion and time to peak expansion.
Intuitively, shorter proliferation rate (B) and higher activation threshold (C) led to delayed
expansion, in some cases being unable to control the malignancy. In fact, products with
a high activation threshold may lead to therapy failure in cases of low presence of CD19-
bearing cells (Figure S3). On the other hand, lower killing capacity implied increased
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expansion. The explanation is clear in the light of the model equations: when the CAR
T-cells were unable to eliminate leukemic cells, the activation function F(t) remained
active and proliferation continued, until there were enough CAR T-cells to reduce the
leukemia burden.
(A) (B) (C)Leukemic Leukemic Leukemic










Figure 5. Influence of CAR T product characteristics. Evolution in time of leukemic cells (gray) and total CAR T-cells
(orange) for different CAR T product attributes (In decreasing order: solid, dashed, dotted lines). Initial state is B0(0) = 106
cells, B1(0) = 3 × 107 cells, B2(0) = 2 × 108 cells, B3(0) = 9 × 107 cells, L(0) = 2 × 1011 cells, CA(0) = 5 × 107 cells and
CM(0) = 0 cells. The remaining parameter values are those of Table 1 with α = 3 × 10−10 day−1 · cell−1 and h = 5 × 108
cells. (A) influence of killing capacity; (B) influence of proliferation rate; (C) influence of activation threshold.
We next aimed to analyze the influence of simultaneous perturbation of two parame-
ters. This can not be done as in the previous figures since it is not possible to distinguish
which parameters are responsible for which changes in the dynamics. For this reason,
we chose to analyze their influence not on the dynamics but on the final state of the sim-
ulation: response vs. no response. The goal was to identify regions of the parameter
space related to either endpoint. In Figure 6A, we show the number of leukemic cells at
day +30 (L30), in logarithmic scale, for pairwise combinations of parameters α, ρC and h,
while keeping the excluded parameter constant. The first month is the time at which bone
marrow is first monitored after infusion [14,22]. Each parameter range was discretized
into 200 evenly spaced values (linearly spaced for ρC and logarithmically spaced for α
and h). We note that the killing capacity α was the least important parameter, observing
more variation over the ranges of the activation threshold and proliferation rate. As seen
in the previous figure, higher proliferation rates and lower activation thresholds were
required for a complete response. To illustrate the evolution with the time of CAR T-cells,
leukemic cells, and B cells in these scenarios, Figure 6B gives six examples of the results
of the model simulations for the first six months of treatment. The three CD19+ B-cell
compartments B1, B2, and B3 are plotted together. For each heatmap, we show an example
of a responding (R) and a non-responding (NR) patient. Responding patients were defined
by the absence of leukemic cells at day 30 (L30 < 1). Non-responding patients are defined
as those with the presence of leukemic cells on that same day (L30 ≥ 1). The interesting
feature of this figure is in analyzing the variety of possible responses. The three responding
patients displayed here showed similar behavior, comparable to that of Figure 3: Expansion
followed by decay and oscillations. We found that the disease could be controlled for a
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range of fold expansions. The relative proportion of activated to memory cell was constant,
since we were not modifying transition rates γAM and γMA. The level of steady state
CAR T-cells did change and was related to the magnitude of the initial expansion. For the
non-responding patients, we observed more variety. First of all, disease recurrence can
occur for different magnitudes of expansion, from one to three orders of magnitude (bottom
and middle subfigures, respectively). Secondly, this recurrence is detectable from the first
to the third month after infusion (top and middle subfigures, respectively). The level of
B cells increased at the time of relapse, while responding patients (left column) showed
no increase. This supports the reported association between BCA and therapy response
(B-cell recovery indicates a possible relapse). Leukemic cells and CAR T-cells were also
subject to the oscillations that were observed in responding patients, and correspond to
cycles of reactivation and decay. Although this model is not reducible to a Lotka–Volterra
model, due to the existence of an activation function, these cycles can be interpreted in
the same way: an increase in leukemic cells occurred after the decay of activated CAR
T-cells, which then regrew in response to the recurring clone. Interestingly, in some cases,
the therapy was able to control the disease after relapse. This behavior has been observed
in simulations of simpler models. In previous work [36], we already remarked that this
scenario would not be observed in the clinical context due to the prompt actions taken
after any signs of disease recurrence. Therefore, while from the dynamical point of view
one could describe some cases as ‘Delayed Response’, from the clinical point of view, they
would still be considered as ‘No Response.’ Finally, leukemic cells and CAR T could also
coexist in equilibrium (top subfigure, NR column).
We finally analyzed the influence of simultaneous perturbations of the three parame-
ters. We run 4000 simulations with α, h and ρC varying in the ranges specified throughout
this section. Specifically, we took 10 evenly spaced values of ρC in the interval 0.4–1;
20 logarithmically spaced values of α in the range 5 × 10−11–5 × 10−9 and 20 logarith-
mically spaced values of h in the range 5 × 108–5 × 1010. We identified responding and
non-responding patients as explained above and computed the level of expansion of CAR
T-cells, defined as log(Cpeak/C0), and the time to peak expansion tpeak for each group.
Results are shown in Figure 7. This particular range and number of simulations yielded
a proportion of responding to non-responding patients of 80 to 20, similar to the early re-
sponse rate recorded in clinical trials [17]. Non-responding patients took longer to achieve
the maximum level of CAR cells and had lower fold expansion (Figure 7B. p < 10−26,
Wilcoxon rank-sum test).
The aim of the previous two figures was to identify the parameters with the greatest
influence on the outcome of the treatment. Another way to understand the relationship
between them is to analyze their influence not on the outcome but on the dynamics (the
values of the different variables). To perform this, we carried out Sobol’s sensitivity
analysis [52] as done in a previous work [36]. This measures the fractional contribution of
a single parameter to the output variance. The results show that product attributes remain
the most relevant parameters (Figures S4 and S5).
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Figure 6. Exploration of parameter ranges for the dynamics of Responding (R) and Non–Responding (NR) patients. (A)
number of leukemic cells at day +30, in logarithmic scale, for different regions of the parameter space. The unchanged
product attribute is displayed on the y-axis. The remaining parameter values are those from Table 1; (B) examples of
responding and non-responding patients for the first six months of therapy. Parameter values are marked in subfigure
(A). Represented are activated and memory CAR T-cells (solid and dotted orange line, respectively), leukemic cells (solid
gray line) and CD19−1 and CD19+ B cells (solid and dotted blue lines, respectively). The initial state of the simulations
in this figure is B0(0) = 106 cells, B1(0) = 3 × 107 cells, B2(0) = 2 × 108 cells, B3(0) = 9 × 107 cells, L(0) = 2 × 1011 cells,
CA(0) = 5 × 107 cells and CM(0) = 0 cells.
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Figure 7. Characteristics of product expansion for Responding (R) and Non-Responding (NR) patients. (A) graphical representation,
on a typical simulation, of the characteristics of the product expansion; (B) differences in time to peak and fold expansion for 4000
simulated patients with parameters from Table 1 and α in the range 5 × 10−11–5 × 10−9 day−1 · cell−1, h in the range 5 × 109–5 × 1011
cells and ρC in the range 0.4–1 day−1. Initial state was set to B0(0) = 106 cells, B1(0) = 3 × 107 cells, B2(0) = 2 × 108 cells,
B3(0) = 9 × 107 cells, L(0) = 2 × 1011 cells, CA(0) = 5 × 107 cells and CM(0) = 0 cells. The boxplot shows median and first and
third quartiles.
3.5. Second Infusion in Non-Responding Patients May Improve the Therapy Outcome
A common therapeutic solution for non-responding patients is to reinfuse the original
product, opening the door to the design of dose fractionation schemes. Studies of opti-
mal combinations of timing and dosage are common in chemotherapy and radiotherapy
regimes. The main difference here is that CAR T-cells expand and operate in relation to the
cancer, so standard pharmacokinetic and pharmacodynamic approaches are not applicable.
We explored this issue using the mathematical model. For the three non-responding
patients in Figure 6, we simulated repeated CAR T-cell therapy in three different ways. First,
when the leukemia reached 108 cells, a second dose of 5× 108 CAR T-cells from the original
product was reinfused in silico (Figure 8A). Secondly, we did the same thing but increasing
the number of cells injected in the second dose (Figure 8B). Finally, we simulated the
infusion of a newly manufactured product with improved attributes (Figure 8C), according
to the exploration performed in the previous subsection. We observed that a standard
re-infusion was not enough to control the relapse. A higher dose could be effective in a
subset of patients, while infusing an improved product turned out to be the best option.
This agrees with the previous findings that the interaction of product and cancer is critical
to understand the therapy outcome. Unlike chemotherapeutic drugs, which are typically
modeled as a decaying concentration, this therapy expands and contracts depending on the
target. These tangled dynamics are responsible for the qualitative differences with a typical
dose fractionation scheme, and suggests the need for a deeper investigation of the molecular
basis of T-cell and cancer cell interaction. When infusing a different improved CAR, this
second product eventually became dominant in the CAR T-cell subpopulation (Figure S6).
Clonal dynamics of this kind within the product have already been reported [53], opening
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the door to an evolutionary exploration of the therapy, another feature that is absent in
other types of treatment.
Standard High-dose New product
(A) (B) (C)
Figure 8. Effect of a second infusion of CAR T-cells in non-responding patients. Dynamics of leukemic cells, B cells and CAR
T-cells for the three non-responding patients in Figure 6. (A) standard second dose of 5 × 108 CAR T-cells; (B) increased
second dose of 5× 109 CAR T-cells; (C) second dose of 5× 108 CAR T-cells of a newly-manufactured product with improved
attributes. For the first patient, the new attributes were h = 5 × 108 and ρC = 0.9. For the second patient, the new attributes
were h = 5 × 108 and α = 6 × 10−10. For the third patient, the new parameters were α = 5 × 10−8 and ρC = 0.7. We show
activated and memory CAR T-cells (solid and dotted orange line, respectively), leukemic cells (solid gray line) and CD19−
and CD19+ B cells (solid and dotted blue lines, respectively). The red vertical line represents the time of the second infusion.
The initial state for the simulations and the other parameter values were as in Figure 6.
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To explore the full range of product attributes, we repeated the simulations shown
in Figure 6 with the reinfusion protocol. As explained above, a second dose was given
when leukemia reached 108 cells or the highest value below that number. Where there was
no initial response, a second dose was infused computationally at day +30. The results
showed that the regions associated with success and failure remained invariant, reinforcing
the conclusion that a single reinfusion of the original product would not be a successful
strategy in general (Figure S7).
4. Discussion
CAR T-cell therapy is the most promising therapeutic option for recurrent B-cell acute
lymphoblastic leukemia in children. The recent approval of the first drug by the US and
EU drug administrations has culminated three decades of research in adoptive transfer of
autologous, genetically modified T-cells. Clinical trials have shown good rates of response
and long-term remission. After four generations, the CAR T construct has achieved enough
expansion and persistence potential to induce successful responses. The persistence of CAR
T-cells in the organism, acting as a surveillance mechanism, is thought to be promoted by
the continuous generation of B cells in bone marrow, acting as an endogenous vaccine [24].
The interaction between renewing B cells, CAR T-cells, and leukemic cells in the bone
marrow is therefore likely to predict the outcome of the therapy. The lack of extensive bone
marrow data due to the more invasive way it must be extracted means that other means of
studying these dynamics must be explored.
In this study, we aimed to incorporate into mathematical models two elements that
have been reported to be important by clinical research. The first was the role of bone
marrow as a source of CAR T-cell ongoing stimulation, due to the production of B cells.
The second was the kinetics of the product, which had been characterized by a biphasic
decline and explained by the existence of two CAR T subpopulations, one effector, the other
memory. This was done by building on previous mathematical models of B cell develop-
ment and CAR T therapy, which had underlined the importance of B cell production in
determining therapy outcome. Contrary to the usual mass action term for the proliferation
of the CAR T-cells, we followed previous models of T-cell response and included an acti-
vation function. In this way, we accounted for the antigen-independent features of T-cell
response. With this, we mean that T-cells commit to a given clonal expansion upon activa-
tion; the role of the antigen is the initiation of this process and not the determination of the
proliferation rate, as would happen in Lotka–Volterra models. Antigen thus functions as
an on-off switch (we show this in Figure S8 for simulations in Figures 2 and 3). The result
of these assumptions was a mathematical model of seven ordinary differential equations,
with many of the parameters already studied or available from clinical data.
Our first goal was to reproduce the known kinetics of the product and the clinical
observations related to the therapy. By omitting the equations related to B-cell production,
we were able to recover the characteristic curves reported from clinical trials with the
biphasic decline in the number of CAR T-cells. We then simulated the production of B
cells, describing the differences with the dynamics in peripheral blood. We observed the
reactivation of CAR T-cells due to the recovery of B cells and the achievement of a steady
state which accounted for both the persistence of the drug and the absence of B cells in blood.
The model predicted relative proportions of B-cell subsets and CAR T subsets directly
attainable from the flow cytometry data of long-term remission patients. In particular,
the reorganization of the B-cell subsets, with a predominant CD19− compartment, has
recently been reported in patients who respond to anti-CD19 therapy [54]. This otherwise
unnoticeable precursor could reach up to 100% of all the B-cell precursors, as shown here.
We also noted that peripheral blood and bone marrow dynamics were similar during the
first month of therapy, clarifying the relevance of this time scale in assessing response. One
of the first clinical trials described recovery of hematogones or normal B-cell progenitors in
bone marrow from day 28 onwards, which matches the simulations of our model [15].
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Our second goal was to identify which parameters were most relevant in relapse. We
first assessed the importance of the initial quantities of B cells, leukemic cells, and CAR
T-cells. None of these factors seemed to influence expansion and outcome. With respect
to leukemia burden or initial B-cell population, clinical trials have reported either no
influence or contradictory evidence [22,24,55,56]. There is more agreement about the lack
of relationship between dose and response [57]. We then evaluated the influence of CAR T
product characteristics, with the hypothesis that some phenotypic properties of the CAR
T-cells are associated with lack of response [58]. We showed that proliferation rate ρC
and activation threshold h are relevant in determining response. This seems reasonable,
since these are the two factors that have been the subject of improvement in the different
generations of CAR T-cells. In fact, early generations failed due to impaired activation
and expansion [59]. We also showed that a high activation threshold could explain those
cases in which low antigen burden is associated with therapy failure [58]. On the other
hand, we observed rather counterintuitive behavior when varying the killing capacity
α. Lower values of killing capacity meant increased expansion, due to the continuous
activation caused by leukemic cells that the drug was not able to eliminate. This contradicts
the observed fact that non-responding patients have reduced expansion. Nonetheless,
when the whole range of parameters was evaluated, we found significant differences in
expansion between the groups of responding and non-responding patients. In addition,
in some cases, non-responding patients expand normally. CD19+ relapses could then be
explained by the impaired effector capacity of the CAR T-cells. The literature suggests that
this could be induced by leukemic cells themselves [60], which is something to explore in
future works. Non-responding patients were also shown here to reach maximum expansion
later than responding patients, which also agrees with clinical observations. In this case,
however, clinical differences were more pronounced [6]. In support of this counterinituitive
result, some studies have shown that a product with lower affinity, which here means a
lower killing capacity, can yield better results in expansion and persistence [61,62]. Finally,
the sensitivity analysis showed that parameter α was especially important for the dynamics
of CAR T-cells, while h and ρC were more relevant for the dynamics of B-cells and leukemic
cells. Note, however, that a parameter can have influence on the dynamics but not on the
endpoint of the therapy, as happened with parameter α.
We then used the mathematical model to test, in silico, the effectivity of a second dose
of CAR T, a procedure that has been carried out in patients that did not respond to the
first infusion. We showed that the same product is unlikely to control the disease, while
increasing the dose, and especially improving the quality of the product, could be more
impactful. Clinical trials have precisely reported little to no success of reinfusions [15,16,63],
which could also be related to the lack of lymphodepleting chemotherapy and/or the
role of regulatory T-cells. A recent study identified the factors associated with complete
response after second infusions [64]. These are mainly a higher dose, as reported here,
and lymphodepleting chemotherapy before the first dose. Failure of the second dose has
also been attributed to the development of an immune response against the CAR T [65]. We
showed here that it could be due to the dynamical nature of the interaction: The outcome
is determined by the parameters that control this interaction, and not by the amounts
involved or by their timing, as would happen with chemotherapy. For this reason, rather
than dose-fractioning schemes, the optimal course of action would be to search for ways
to affect this interaction. For example, infusions of T-cell specific antigen-presenting cells
have been shown to boost anti-tumor response [58,66]. In this line, the model predicts that
infusion of B-cells upon relapse could potentially control the disease or delay recurrence in
some cases (Figure S9).
A recent review of mathematical models of CAR T-cell therapy [25] suggested a num-
ber of requisites that any of these models should include to provide a faithful description
of the biological dynamics. The model presented here succeeds in recapitulating antigen-
driven expansion, bi-exponential decay, and a limited expansion despite large antigen
burden. It does so without depending on a piecewise definition of the model, integrating
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both expansion and decay in the same mathematical framework. The model also allowed
for the accommodation of multiple dosages. A point of disagreement with this review
was the oscillatory behavior of CAR T-cells and B cells, declared as an undesirable feature.
In our case, they can be explained analogously to predator–prey dynamics, although the
system is not directly reducible to a Lotka–Volterra system of equations. Interestingly,
behavior of this kind in bone marrow has been recently reported by a clinical trial [67].
In addition, these cycles were predicted to occur in the bone marrow, where B cells are
produced, and not in peripheral blood, which is where the kinetics of the product are
normally assessed. Given the length and amplitude of the cycles shown here, current
protocols of bone-marrow extraction might not be able to detect this phenomenon within
the precision of cell abundance determinations.
The model presented here, despite its success in representing a range of clinical
observations, is missing some features of non-responding patients. First of all, CD19−
relapses demand a different modeling approach, or the addition of more compartments,
possibly including Darwinian selection processes like preexisting CD19− leukemic clone
selection or CD19 downregulation [68]. With respect to CD19+ relapses, the model was not
able to capture long-term relapse, occurring from month three onwards. We have observed
here that, from this date, the system typically reaches a steady state, in coexistence with
either healthy B cells (in responding patients) or both leukemic clone and B cells (in non-
responding patients). A steady state of this kind is consistent with patients in whom BCA
has been ongoing for long periods of time, but not those who either relapse or recover B
cells in peripheral blood in the meantime. In addition, differences in expansion and time to
maximum expansion between responding and non-responding patients should be larger.
This may be due to our arbitrary selection of parameter values in their respective ranges,
or to the fact that we did not take into account correlations between them. Nonetheless, we
cannot discard the possibility that other processes are at work.
Some biological elements may be needed in more exhaustive mathematical models,
able to account for more biological phenomena present in CAR T-cell treatments. First,
mechanisms of T-cell exhaustion could help in accounting for long-term relapses. These
mechanisms are thought to be linked to excessive stimulation or activation [69], and are
often found in persistent infections such as lymphocytic choriomeningitis (LCM) or cy-
tomegalovirus (CMV) [70]. A mechanism of this kind would attenuate the excessive
expansion in patients with lower killing capacity, leading to the death of CAR T-cells
subjected to continuous stimulation. It should also explain the loss of the CAR T-cells
in situations of coexistence with the leukemic cell population, which demands sustained
activation and effector functions. Finally, it should also account for the loss of the product
after longer periods of coexistence with B cells, which are not as demanding to the CAR T
as the clone from the immunological point of view. This would also cause the attenuation
of the cycles of expansion and decay.
A second biological element that should be accounted for in mathematical models is a
more detailed description of the process of activation, differentiation, and renewal of CAR
T-cells. This part of the system has been shown to be more significant than, for example,
the compartmentalization of B-cell development or the initial state. Along these lines,
there are studies that explain how the specific subsets of T-cells in the initial leukapheresis
can be a determinant of the response. For example, central memory T-cells can yield a
more effective product than other phenotypes [17]. This suggests that, while a separation
in effector and memory T-cells is enough to represent the kinetics of the drug, a more
detailed description of the subsets could be necessary to explain and interpret therapy
outcome. One last aspect of interest is the influence of CD19 surface density on activation
and elimination. While this has not been reported to have a significant influence [71],
contrary to other markers like CD22 [72], infused product data could help elucidate its role.
This feature could be included in a more complex model that incorporates CD19 expression
as another variable.
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5. Conclusions
We have presented a mathematical model of CAR T-cell therapy in bone marrow that
is able to explain a number of clinical features that have been observed. It can account for
the measured kinetics of the drug and for the coincidence of BCA and CAR T persistence. It
also agrees in attributing more relevance to product characteristics in determining response.
Some of the predictions and properties of the model are easily testable from already existing
clinical data, for example by adding panels for B cells and T-cells in flow cytometry data.
Relative proportions of these cellular subpopulations could help in parameterizing this
and other models of CAR T therapy response. The mathematical model also suggests
the importance of characterizing the composition of both the infused product and the
patient’s initial T-cell repertoire. Simple improvements of the mathematical model could
explain additional observations, possibly including a more detailed description of the T-cell
compartment and the consideration of mechanisms of T-cell exhaustion.
We hope that this study will stimulate mathematical research in this interesting area,
in which in-silico modeling can help in finding optimal therapeutic schedules and in
suggesting ways for improving treatments with these promising immunotherapies.
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